The takeover is part of a service expansion programme for Novotech’s international client base.
An Asia-Pacific biotech specialist CRO, Novotech offers full-service, high-quality accelerated clinical trials in the region.
With the acquisition of NCGS, Novotech could provide clinical services to its biotech clients in the US to carry out late-stage international trials.
Novotech CEO Dr John Moller said: “This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programmes.”
“Clients will receive seamless service, with a unified approach to systems and SOPs well developed.”
To serve biotechs across the globe, Novotech uses its deep associations created with several Asia-Pacific sites over the past 25 years.
NCGS supports this approach with an extensive site base in the US comprising hundreds of investigators with associations spanning nearly 40 years.
NCGS founder and CEO Nancy Snowden said: “Novotech and NCGS have a longstanding collaboration history of over a decade which will also support the seamless integration.”
“NCGS focuses on complex areas of clinical development; oncology, haematology, infectious disease, and CNS in both adult and paediatric populations.
In January this year, Novotech entered a strategic collaboration with healthcare data technology company Prospection to merge the power of real-world data and clinical trials to deliver therapies to patients rapidly.
Under the deal, Novotech will invest in Prospection, with the latter becoming a technology partner of the company.
Prospection will offer real-world data analytics for trial feasibility analysis, execution and recruitment in the Asia-Pacific region.